Beta Bionics, INC Form 4 insider transactions

Beta Bionics Director Gerard J. Michel received an award of 3,997 restricted stock units under the company's 2025 Equity Incentive Plan.

Beta Bionics Director Sean Carney received an award of 3,997 restricted stock units under the company's 2025 Equity Incentive Plan.

Beta Bionics Director Maria Palasis was granted 3,997 shares of common stock as a restricted stock unit award.

Beta Bionics, Inc. Director Christy Jones was granted 3,997 restricted stock units, aligning her interests with shareholders.

Beta Bionics Director Adam Lezack was granted 3,997 restricted stock units under the company's 2025 Equity Incentive Plan, increasing his beneficial ownership to 12,432 shares.

Beta Bionics Director Danny L. Dearen was granted 3,997 restricted stock units under the company's 2025 Equity Incentive Plan.

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 2,200 shares of common stock for a weighted average price of $30.1005 per share under a pre-arranged 10b5-1 plan.

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 7,800 shares of common stock on January 2, 2026, under a pre-arranged 10b5-1 trading plan.

Beta Bionics' Chief Financial Officer, Stephen Feider, executed a pre-planned sale of 20,000 common shares following the exercise of stock options.

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 1,063 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Beta Bionics' Chief Financial Officer, Stephen Feider, sold 1,427 shares of common stock at $29.3359 per share to cover tax withholding obligations.

Beta Bionics President & CEO Sean Saint sold 3,278 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Beta Bionics Director Adam Lezack sold 1,406 shares of common stock on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

Beta Bionics Director Maria Palasis sold 1,406 shares of common stock on December 1, 2025, under a pre-arranged 10b5-1 plan.

Beta Bionics Director Adam Lezack sold 1,406 shares of common stock on October 31, 2025, under a pre-arranged 10b5-1 plan.

Beta Bionics Director Maria Palasis sold 1,406 shares of common stock for approximately $38,000 under a pre-arranged 10b5-1 trading plan.

Beta Bionics CFO Stephen Feider exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Beta Bionics' Chief Financial Officer, Stephen Feider, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Beta Bionics' Chief Financial Officer, Stephen Feider, executed a planned sale of 9,900 shares following the exercise of stock options.

Beta Bionics' Chief Commercial Officer, Mark Hopman, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Beta Bionics CFO Stephen Feider exercised options and sold 100 shares of common stock on September 5, 2025, under a pre-arranged 10b5-1 plan.

Beta Bionics President and CEO, Sean Saint, sold 3,359 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Beta Bionics' Chief Medical Officer, Steven Jon Russell, sold 1,015 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 1,089 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Beta Bionics' Chief Commercial Officer, Mark Hopman, sold 848 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Beta Bionics' Chief Financial Officer, Stephen Feider, sold 1,462 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Beta Bionics CFO Stephen Feider exercised stock options and subsequently sold 4,413 shares of common stock for a profit, as disclosed in a recent Form 4 filing.

Beta Bionics Chief Commercial Officer Mark Hopman sold 16,158 shares of common stock for approximately $268,361 after exercising options.

Beta Bionics' Chief Financial Officer, Stephen Feider, sold 5,587 shares of common stock for $17.0345 per share after exercising options, as part of a pre-arranged trading plan.

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., sold 868 shares of common stock on June 2, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.